Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, ...

PLX READ THE FULL PLX RESEARCH REPORT 2024 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 2024 financial and operational results in a March 17th, 2024 press ...

IceCure Medical Ltd.  ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.